ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) rearrangement with aberrant ALK-fluorescence in situ hybridization (FISH) patterns can be detected in CTCs in concordance with patients having ALK-positive NSCLC, enabling both diagnostic testing and decision-making for ALK inhibitors.